A5020885726- HIV Research and Treatment
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Phytochemistry and biological activity of medicinal plants
- HIV/AIDS drug development and treatment
- vaccines and immunoinformatics approaches
- Pharmacological Effects of Natural Compounds
- Luminescence and Fluorescent Materials
- RNA modifications and cancer
- Flavonoids in Medical Research
- Quinazolinone synthesis and applications
- Carbon and Quantum Dots Applications
- Antibiotics Pharmacokinetics and Efficacy
- Morinda citrifolia extract uses
- Plant pathogens and resistance mechanisms
- Barrier Structure and Function Studies
- COVID-19 Clinical Research Studies
- Microfluidic and Capillary Electrophoresis Applications
- Herpesvirus Infections and Treatments
- Analytical chemistry methods development
- Peptidase Inhibition and Analysis
- Natural product bioactivities and synthesis
- Plant Pathogenic Bacteria Studies
- SARS-CoV-2 and COVID-19 Research
University of Massachusetts Chan Medical School
2015-2024
China Pharmaceutical University
2016-2019
University of Worcester
2016
Northeast Agricultural University
1995
The current study aims to develop a safe and highly immunogenic COVID-19 vaccine. novel combination of DNA vaccine encoding the full-length Spike (S) protein SARS-CoV-2 recombinant S1 induced high level neutralizing antibody T cell immune responses in both small large animal models. More significantly, co-delivery components at same time elicited full protection against intratracheal challenge viruses immunized rhesus macaques. As vaccines have been proven previous human studies, are capable...
Abstract The vaccine elicitation of HIV tier-2-neutralization antibodies has been a challenge. Here, we report the isolation and characterization CD4-binding site (CD4bs) specific monoclonal antibody, HmAb64, from human volunteer immunized with polyvalent DNA prime-protein boost vaccine. HmAb64 is derived heavy chain variable germline gene IGHV1-18 light IGKV1-39. It third complementarity-determining region (CDR H3) 15 amino acids. On cross-clade panel 208 HIV-1 pseudo-virus strains,...
The fourth conserved region (C4) in the HIV-1 envelope glycoprotein (Env) gp120 is a structural element that important for its function, as it binds to both receptor CD4 and co-receptor CCR5/CXCR4. It has long been known this highly immunogenic harbors B-cell well T-cell epitopes. target of number antibodies animal studies, which are called CD4-blockers. However, mechanism by virus shields itself from such antibody responses not known. Here, we determined crystal structure R53 complex with...
The synthesized N,S-CDs was firstly used as a matrix for small molecule analysis with good reproducibility, high sensitivity and salt tolerance.
Hypoxia is a general event in solid tumor growth. Therefore, induced cellular responses by hypoxia are important for tumorigenesis and MicroRNAs (miRNAs) have recently emerged as regulators of responses. Here we report that miR-147a novel crucial miRNA. HIF-1α up-regulates the expression miR-147a, turn stabilizes accumulates protein via directly targeting HIF-3α, dominant negative regulator HIF-1α. Subsequent studies xenograft mouse model reveal capable inhibiting Collectively, these data...
Antibodies are principal immune components elicited by vaccines to induce protection from microbial pathogens. In the Thai RV144 HIV-1 vaccine trial, efficacy was 31% and sole primary correlate of reduced risk shown be vigorous antibody response targeting V1V2 region envelope. against V3 also were inversely correlated with infection in subsets vaccinees. recognizing these regions, however, do not exhibit potent neutralizing activity. Therefore, we examined antiviral potential poorly...
Envelope (Env) glycoprotein of human immunodeficiency virus type 1 (HIV-1) is an important target for the development HIV vaccine. Extensive glycosylation Env feature that both protects from antibody responses and serves as a some highly potent broadly neutralizing antibodies. Therefore, analysis glycans on recombinant proteins significant. Here, we present profiles gp120 four major clades HIV-1 (A, B, C, AE), produced either research-grade material in 293 CHO cells or two independent lots...
Blood and tissue pharmacokinetics drug residue profiles of six chemotherapeutants were studied. Ceftriaxone (CEF), intravenously at 50 mg/kg, sulfamonomethoxine (SMM) sulfaquinoxaline (SQ), orally 200 olaquindox (OLA), administered to young broilers. Penicillin (PEN), intramuscularly 000 U/kg, albendazole (ALB), 20 given rabbits. For each drug, 13–18 groups ( n = 5–10 individuals/group) the dosed animals killed different post‐dosing times. Drug and/or metabolite concentrations in plasma,...
While DNA prime-protein boost vaccination approach has been widely used in preclinical and clinical studies especially the field of HIV vaccine development, exact role immunization not fully identified. Our previous work demonstrated that was able to elicit T follicular helper (Tfh) cell responses germinal center (GC) B development a mouse model. In current report, immunogenicity study conducted further ask whether is antigen-specific responses. Using HIV-1 Env as model antigen delivered...
A high performance liquid chromatography-tandem mass spectrometry method was developed to investigate the influence of wine-processing on pharmacokinetics anthraquinones from rhubarb in hyperlipidemic hamsters.
Since publishing our original reports on the safety and immunogenicity of a polyvalent DNA prime-protein boost HIV vaccine (PDPHV) which elicited high titer antibody responses with broad specificity, neutralizing activities to multiple HIV-1 subtypes, as well poly-functional T cell responses, accumulated findings from other studies indicated important roles Ig isotype distribution, Fc medicated functions persistence memory immune were not studied in previous PDPHV related reports. The...
Our previous preclinical studies and a Phase I clinical trial DP6-001 have indicated that polyvalent Env formulation was able to elicit broadly reactive antibody responses including low titer neutralizing against viral isolates of subtypes A, B, C AE. In the current report, panel 62 gp120 immunogens were screened in rabbit model identify can improved binding some them be included next formulation. Only about 19% this antibodies greater than 50% viruses high throughput PhenoSense...